(107 days)
Yes
The device description explicitly states that it utilizes "deep learning technology" and is a "deep-learning based software analysis package" with a "deep learning bone segmentation algorithm." Deep learning is a subset of machine learning.
No.
This device is an image processing software that provides optimized visualization of bone marrow; it does not directly treat or diagnose a disease.
No.
The device is a software application that assists clinicians by optimizing the visualization of bone marrow from CT images. It does not provide a diagnosis itself, but rather facilitates the review of pathologies by generating fused material density images for optimized visualization.
Yes
The device is described as a "software application" and "software analysis package" that processes existing CT images. It does not mention any accompanying hardware components or hardware-specific functions beyond processing data from GE HealthCare's spectral CT acquisitions.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, tissue) to provide information for the diagnosis, monitoring, or treatment of a disease or condition.
- Device Function: The Spectral Bone Marrow software processes medical images (CT scans) of the human body. It does not analyze specimens taken from the body. Its purpose is to enhance the visualization of bone marrow within these images to aid in the review of bone pathologies.
- Intended Use: The intended use clearly states it's for "facilitate optimized visualization of bone marrow in spectral body and extremity CT images" and "can be used during the review of traumatic and non-traumatic bone pathologies." This is focused on image analysis and interpretation, not laboratory testing of biological samples.
Therefore, Spectral Bone Marrow falls under the category of medical image processing software rather than an In Vitro Diagnostic device.
No
The input text does not contain any explicit statement that the FDA has reviewed, approved, or cleared a PCCP for this specific device. The relevant section notes "Control Plan Authorized (PCCP) and relevant text Not Found".
Intended Use / Indications for Use
Spectral Bone Marrow is an automated image processing software application, utilizing deep learning technology for bone segmentation, to facilitate optimized visualization of bone marrow in spectral body and extremity CT images. Spectral Bone Marrow's output can be used during the review of traumatic and non-traumatic bone pathologies.
Product codes
JAK, QIH
Device Description
Spectral Bone Marrow is a deep-learning based software analysis package designed for the visualization of bone marrow based on GE HealthCare's spectral CT acquisitions data. Spectral Bone Marrow assists clinicians by providing an automatically generated fused material density image of the segmented bone region over a base monochromatic image optimized for the visualization of bone marrow during the review of traumatic or non-traumatic bone pathologies. The software creates a fully automated post processing workflow for creating these images and improving reader efficiency.
The Spectral Bone Marrow application involves generating a bone mask with a deep learning bone segmentation algorithm and uses this segmented region to define bone regions of water minus hydroxyapatite (Water(HAP)) material density images, which are subsequently colored. The application outputs the colored Water(HAP) material density images overlayed on monochromatic CT images or Virtual Unenhanced (VUE) images.
Additionally, the Spectral Bone Marrow application has the optional ability to automatically set the window width and window level of the color overlay images to provide for optimal visualization of bone marrow. The software provides multiplanar export of the fused images. Spectral Bone Marrow is hosted on GE's Edison Health Link (EHL) computational platform.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Yes
Input Imaging Modality
CT (Computed Tomography)
Anatomical Site
Body and extremity
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Clinicians (Radiologists specifically)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A database of 146 retrospective Spectral CT series across a variety of GEHC Spectral Imaging CT Scanners. The ground truth for this dataset was generated by three US board certified radiologists, which was used to evaluate the Spectral Bone segmentation.
Summary of Performance Studies
Non-clinical testing: Engineering bench testing was carried out to verify the Spectral Bone Marrow's bone segmentation algorithm ability to accurately segment bone using a database of 146 retrospective Spectral CT series. The result showed that the algorithm is capable of accurately segment bones and is safe and effective for its intended use.
Clinical testing: A representative set of clinical sample images was assessed by three board certified radiologists with expertise in both the evaluation of bone marrow and dual energy imaging review. The assessment used retrospectively collected clinical cases that were processed using the Spectral Bone Marrow software. Each image generated from the subject device were read by each board certified radiologist who provided an assessment of image quality related to diagnostic use according to a Likert scale. Additionally, the readers were asked to rate their efficiency when using the algorithm compared to using without. The result validated that the Spectral Bone Marrow software provides additional diagnostic value for the evaluation of bone marrow and increased overall reader efficiency.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1750 Computed tomography x-ray system.
(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.
0
March 9, 2023
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is a blue square with the letters FDA in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
GE Medical Systems, LLC. % Katelyn Rowley Senior Regulatory Affairs Leader 3000 N. Grandview Blvd. WAUKESHA WI 53188
Re: K223514
Trade/Device Name: Spectral Bone Marrow Regulation Number: 21 CFR 892.1750 Regulation Name: Computed Tomography X-Ray System Regulatory Class: Class II Product Code: JAK, QIH Dated: February 21, 2023 Received: February 22, 2023
Dear Katelyn Rowley:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Lu Jiang
Lu Jiang, Ph.D. Assistant Director Diagnostic X-Ray Systems Team DHT8B: Division of Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K223514
Device Name Spectral Bone Marrow
Indications for Use (Describe)
Spectral Bone Marrow is an automated image processing software application, utilizing deep learning technology for bone segmentation, to facilitate optimized visualization of bone marrow in spectral body and extremity CT images. Spectral Bone Marrow's output can be used during the review of traumatic and non-traumatic bone pathologies.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/2 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized font in the center. There are three white swirls around the outside of the circle. The logo is simple and recognizable.
510(k) SUMMARY OF SAFETY AND EFFECTIVNESS
This 510(k) summary of Safety and Effectiveness information is submitted in accordance with the requirement of 21 CFR Part 807.87(h):
- Date: November 22, 2022 Submitter: GE Medical Systems, LLC 3000 N. Grandview Blvd. Waukesha, Wisconsin 53188
- Primary Contact: Katelyn Rowley Senior Regulatory Affairs Leader Phone: 262-309-5888 Email: Katelyn.rowely@ge.com
- Secondary Contacts: Helen Peng Senior Regulatory Affairs Director Phone: 262-424-8222 Email: hong.peng@med.ge.com
| Device Trade Name: | Spectral Bone Marrow |
|---|---|
| Device Classification | Class II |
| Regulation Number/ | 21 CFR 892.1750 Computed tomography x-ray system / JAK |
| Product Code: | 21 CFR 892.2050 Automated Radiological Image Processing Software / QIH |
| Predicate Device Information | |
|---|---|
| Device Name: | GSI Viewer with VUE Option |
| Manufacturer: | GE Medical Systems, LLC |
| 510(k) Number: | K121827 cleared on September 13, 2012 |
| Regulation Number/ | |
| Product Code: | 21 CFR 892.1750 Computed tomography x-ray system / JAK |
Device Description
Spectral Bone Marrow is a deep-learning based software analysis package designed for the visualization of bone marrow based on GE HealthCare's spectral CT acquisitions data. Spectral Bone Marrow assists clinicians by providing an automatically generated fused material density image of the segmented bone region over a base monochromatic image optimized for the visualization of bone
4
Image /page/4/Picture/1 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized font in the center. There are also three white swirls around the edge of the circle. The logo is simple and recognizable, and it is associated with a well-known and established company.
marrow during the review of traumatic or non-traumatic bone pathologies. The software creates a fully automated post processing workflow for creating these images and improving reader efficiency.
The Spectral Bone Marrow application involves generating a bone mask with a deep learning bone segmentation algorithm and uses this segmented region to define bone regions of water minus hydroxyapatite (Water(HAP)) material density images, which are subsequently colored. The application outputs the colored Water(HAP) material density images overlayed on monochromatic CT images or Virtual Unenhanced (VUE) images.
Additionally, the Spectral Bone Marrow application has the optional ability to automatically set the window width and window level of the color overlay images to provide for optimal visualization of bone marrow. The software provides multiplanar export of the fused images. Spectral Bone Marrow is hosted on GE's Edison Health Link (EHL) computational platform.
Indications for Use
Spectral Bone Marrow is an automated image processing software application, utilizing deep learning technology for bone segmentation, to facilitate optimized visualization of bone marrow in spectral body and extremity CT images. Spectral Bone Marrow's output can be used during the review of traumatic and non-traumatic bone pathologies.
Comparisons
The Spectral Bone Marrow software is substantially equivalent to the predicate device GSI Viewer with VUE Option (K121827). The fundamental technology, i.e generating the material density (MD) images, monochromatic images and overlaying the MD images over base images, remains unchanged from the predicate. The table below summarizes the substantive feature/technological differences between the predicate device and the proposed device. The changes described below do not change the fundamental technology and do not raise any issues of safety and effectiveness.
5
GE HealthCare
510(k) Premarket Notification Submission – Spectral Bone Marrow
Image /page/5/Picture/2 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized font in the center. The letters are surrounded by a swirling design that resembles water droplets. The logo is simple and recognizable, and it is often used to represent the company's products and services.
| Specification/
Attribute | GSI Viewer with VUE Option
(Predicate Device, K121827) | Spectral Bone Marrow
(Proposed Device) |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bone
Segmentation
Technology | Manual segmentation | Deep learning based segmentation |
| Clinical Workflow | Manual | Automated - In the predicate device, the user
has to manually segment the bone region,
generate the MD images and fuse it/overlay
them onto the monochromatic base images,
and then export the output images as DICOM
secondary captures and send them to desired
DICOM destinations.
In the subject device, a fully automated
workflow generates the desired images
(colored MD images of the segmented bone
region overlaid on the monochromatic base or
Virtual Unenhanced images) as secondary
capture DICOM objects and networks them to
the preconfigured DICOM destinations (e.g.
PACS) for the user to review.
This change in the subject device greatly
improves the overall efficiency of the review
workflow. |
| Deployment
Environment | CT Console, AW Workstation
(K110834), AW Server (K081985) | CT Console, Edison Health Link (EHL) |
| Algorithm Input | Dual energy DICOM images | Same |
| Algorithm
Output | Dual energy images, including
monochromatic, Virtual
Unenhanced, and material
density images and has the
ability to output fused colored
material density (MD) images
(e.g Water (HAP)) of a
segmented bone region overlaid
on a monochromatic image as
secondary capture DICOM
series. | Fused image of colored material density (MD)
images (e.g water (HAP)) of the segmented
bone region overlaid onto the base
monochromatic spectral CT images or Virtual
Unenhanced images, as secondary capture
DICOM series. |
6
Image /page/6/Picture/1 description: The image shows the logo for General Electric (GE). The logo is a blue circle with the letters "GE" in a stylized font in the center. There are white swirls around the letters. The logo is simple and recognizable.
Determination of Substantial Equivalence
Summary of Non-Clinical Testing
Spectral Bone Marrow has successfully completed the design control testing per our quality system. No additional hazards were identified, and no unexpected test results were observed. Spectral Bone Marrow was designed under GE HealthCare's QMS per the Quality System Regulations of 21CFR 820 and ISO 13485.
The following quality assurance measures have been applied to the development of the system:
- Requirement Definition
- Risk Analysis and Control
- Technical Design Reviews
- Formal Design Reviews
- Software Development Lifecycle
- O Code Review
- Software Unit Implementation O
- Software Integrations and Integration Testing O
- System Testing
- O Safety Testing (Verification)
- Image Performance Testing (Verification) O
- Simulating Use Testing (Validation) O
- . Software Release
The testing and results did not raise different questions of safety and effectiveness than associated with predicate device. We consider the proposed device, Spectral Bone Marrow, is substantially equivalent to the predicate device.
The substantial equivalence is also based on the software documentation for a "Moderate" level of concern.
The non-clinical testing also included engineering bench testing that was carried out to verify the Spectral Bone Marrow's bone segmentation algorithm ability to accurately segment bone using a database of 146 retrospective Spectral CT series across a variety of GEHC Spectral Imaging CT Scanners. This database of exams is representative of the clinical scenarios where Spectral Bone Marrow is intended to be used. The ground truth for this dataset was generated by three US board certified radiologists, which was used to evaluate the Spectral Bone segmentation. The result of the engineering bench testing showed that the algorithm is capable of accurately segment bones and is safe and effective for its intended use.
Clinical Testing
A representative set of clinical sample images was assessed by three board certified radiologists with expertise in both the evaluation of bone marrow and dual energy imaging review. The assessment used retrospectively collected clinical cases that were processed using the Spectral Bone Marrow software. Each image generated from the subject device were read by each board certified radiologist who
7
Image /page/7/Picture/1 description: The image shows the General Electric (GE) logo. The logo consists of the letters "GE" in a stylized script, enclosed within a blue circle. There are also some white curved lines around the circle, giving the impression of movement or energy.
provided an assessment of image quality related to diagnostic use according to a Likert scale. Additionally, the readers were asked to rate their efficiency when using the algorithm compared to using without.
The result of this assessment validated that the Spectral Bone Marrow software provides additional diagnostic value for the evaluation of bone marrow and increased overall reader efficiency.
Substantial Equivalence
The changes associated with Spectral Bone Marrow do not change the Intended Use from the predicate and represent equivalent technology.
Spectral Bone Marrow was developed under GE HealthCare's quality system. Design verification, along with bench and clinical testing provided in this submission demonstrates that Spectral Bone Marrow is substantially equivalent and hence as safe and as effective as the legally marketed predicate device. GE's quality system's design, verification, and risk management processes did not identify any unexpected results, or adverse effects stemming from the changes to the predicate.
GE HealthCare believes that Spectral Bone Marrow is substantially equivalent to the predicate device and hence is safe and effective for its intended use.